{
  "docId": "019de076-3deb-7779-9c43-c38f834a1cfd",
  "docSlug": "60ad9a5894e93b6af8b1b5bddd2d87e3",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 30,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide outlines a standard clinical trial dose escalation design (3+3) for a radiopharmaceutical.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-3deb-7779-9c43-c38f834a1cfd/12",
  "deckHref": "/decks/019de076-3deb-7779-9c43-c38f834a1cfd",
  "deckJsonHref": "/decks/019de076-3deb-7779-9c43-c38f834a1cfd.json",
  "deckAnchorHref": "/decks/019de076-3deb-7779-9c43-c38f834a1cfd#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.55,
        "x": 0.38,
        "y": 0.23
      },
      "kind": "diagram",
      "text": "Dose Escalation: 3+3 Design",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "492014aa-7b73-4e1d-88bd-2bcb57335eb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Initial indications: Pancreatic ductal adenocarcinoma, Colorectal, Squamous cell carcinoma head & neck, Gastric, Ewings sarcoma, NED prostate",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8f18eea-1e3e-41a5-8a3b-fa90e0230adc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Patients with NTSR1+ solid tumors as determined by SPECT/CT imaging",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38b5f636-014c-42ce-ba9f-a2488b81221c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.05,
        "y": 0.76
      },
      "kind": "paragraph",
      "text": "Treatment: [225Ac]-FPI-2059 every 56 days for up to 4 cycles",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9761ca8-2c20-471d-b2eb-d06d50d35169",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "FPI-2059 Development Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86889433-ad72-405f-a598-6baff6be0e62",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "3+3 design",
      "slug": null,
      "matchId": "2abbd332-d043-4b28-8e27-1036b387cd43",
      "evidence": "Standard clinical trial dose escalation methodology",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 10,
      "beatId": "112b9300-e62a-468e-ab16-1feeb3a2395e",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Opportunity",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The document discusses the market opportunity for radiopharmaceuticals and the potential for Fusion Pharmaceuticals' therapies",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}